Literature DB >> 27662820

Advanced Glycation Endproducts Impair Endothelial Progenitor Cell Migration and Homing via Syndecan 4 Shedding.

Jun Xie1, Ran Li1, Han Wu1, Jianzhou Chen1, Guannan Li1, Qinhua Chen1, Zhonghai Wei1, Guixin He1, Lian Wang1, Albert Ferro2, Biao Xu1.   

Abstract

Endothelial progenitor cells (EPCs) are a subtype of bone marrow-derived progenitor cells. Stromal cell-derived factor 1 (SDF-1)-mediated EPC mobilization from bone marrow to areas of ischemia plays an important role in angiogenesis. Previous studies have reported that advanced glycation endproducts (AGEs), which are important mediators of diabetes-related vascular pathology, may impair EPC migration and homing, but the mechanism is unclear. Syndecan-4 (synd4) is a ubiquitous heparan sulfate proteoglycan receptor on the cell surface, involved in SDF-1-dependent cell migration. The extracellular domain of synd4 (ext-synd4) is shed in the context of acute inflammation, but the shedding of ext-synd4 in response to AGEs is undefined. Here we investigated changes in ext-synd4 on EPCs in response to AGEs, focusing on the influence of impaired synd4 signaling on EPC migration and homing. We found decreased full length and increased residue of synd4 in cells incubated with AGEs, with concomitant increase in the soluble fragment of ext-synd4 in the cell medium. EPCs from patients with type 2 diabetes expressed less ext-synd4 as assessed by Western blotting. Flow cytometry analysis showed less ext-synd4 on circulating CD34+ peripheral blood mononuclear cells, of which EPCs form a subgroup. We then explored the role of synd4 in EPC migration and homing. Impaired migration of synd4-deficient EPCs was observed by a 2D-chemotaxis slide. Furthermore, poor homing of synd4-/- EPCs was observed in a mouse model of lower limb ischemia. This study demonstrates that the shedding of synd4 from EPCs plays a key role in AGE-mediated dysfunction of EPC migration and homing. Stem Cells 2017;35:522-531.
© 2016 AlphaMed Press.

Entities:  

Keywords:  Advanced glycation endproducts; Chronic inflammation; Endothelial progenitor cells; Homing; Proteoglycans

Mesh:

Substances:

Year:  2016        PMID: 27662820     DOI: 10.1002/stem.2506

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  7 in total

1.  Resveratrol Improves Tube Formation in AGE-Induced Late Endothelial Progenitor Cells by Suppressing Syndecan-4 Shedding.

Authors:  Han Wu; Zheng Chen; Jian-Zhou Chen; Jun Xie; Biao Xu
Journal:  Oxid Med Cell Longev       Date:  2018-04-10       Impact factor: 6.543

2.  A reduction in the vascular smooth muscle cell focal adhesion component syndecan-4 is associated with abdominal aortic aneurysm formation.

Authors:  Jiaxin Hu; Yuyu Li; Zhonghai Wei; Haiting Chen; Xuan Sun; Qing Zhou; Qi Zhang; Yong Yin; Meng Guo; Jianzhou Chen; Guangyao Zhai; Biao Xu; Jun Xie
Journal:  Clin Transl Med       Date:  2021-12

3.  The effects of YKL-40 on angiogenic potential of HUVECs are partly mediated by syndecan-4.

Authors:  WeiJun Sun; Qi Xue; Yan Zhao; Jianlei Zheng
Journal:  Int J Med Sci       Date:  2021-10-15       Impact factor: 3.738

4.  Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus.

Authors:  Dandan Xie; Yutong Li; Murong Xu; Xiaotong Zhao; Mingwei Chen
Journal:  Cardiovasc Diabetol       Date:  2022-10-03       Impact factor: 8.949

5.  Syndecan-4 Is Increased in Osteoarthritic Knee, but Not Hip or Shoulder, Articular Hypertrophic Chondrocytes.

Authors:  Christelle Sanchez; Cécile Lambert; Jean-Emile Dubuc; Jessica Bertrand; Thomas Pap; Yves Henrotin
Journal:  Cartilage       Date:  2019-08-27       Impact factor: 3.117

Review 6.  Multiple therapeutic effect of endothelial progenitor cell regulated by drugs in diabetes and diabetes related disorder.

Authors:  Rashmi K Ambasta; Harleen Kohli; Pravir Kumar
Journal:  J Transl Med       Date:  2017-08-31       Impact factor: 5.531

Review 7.  Endothelial Progenitor Cells: New Targets for Therapeutics for Inflammatory Conditions With High Cardiovascular Risk.

Authors:  Nicola Edwards; Alexander W W Langford-Smith; Fiona L Wilkinson; M Yvonne Alexander
Journal:  Front Med (Lausanne)       Date:  2018-07-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.